ReviewBiology2026
TLR Signaling Beyond Immunity: Emerging Roles in Cell Migration, Metabolism, Development, and Host-Microbiome Crosstalk.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent findings support a broader view of TLR signaling as an integrative signaling hub that links immunity with cell migration, metabolism, development, and host-microbiome crosstalk. In cell migration, TLRs exert context-dependent effects through chemokine receptor regulation, adhesion and cytoskeletal modulation, and indirect cytokine-mediated signaling. In metabolism, TLRs orchestrate insulin resistance, obesity, and glucose homeostasis in a receptor- and tissue-specific manner. In tissue injury and development, TLR signaling exerts dual roles; it is detrimental in ischemia-reperfusion injury, but beneficial in vascular remodeling and neurogenesis. We then examine the bidirectional interplay between TLRs and the gut microbiome, where TLRs shape microbial community structure and intestinal immune homeostasis. Finally, we survey the therapeutic landscape of TLR modulators, highlighting that while TLR agonists are predominantly explored in oncology, TLR antagonists show promise in autoimmune diseases such as inflammatory bowel disease. Special attention is given to insights from organoid, rodent and zebrafish models, which have provided powerful in vitro and in vivo evidence for multiple roles of TLR signaling under both physiological and pathological conditions. A deeper understanding of these non-canonical functions will be essential for developing next-generation therapeutic strategies that selectively modulate TLR signaling in infectious, inflammatory, metabolic, and microbiome-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.